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Abstract:
Objectives: To evaluate the Beliefs about Medicine Questionnaire to explore adherence to 
adjuvant endocrine therapy after treatment for breast cancer (BMQ-AET). Method: Factor 
structure of the BMQ-AET was explored alongside internal consistency, convergent validity 
and acceptability. Results: The BMQ-AET Specific Scale fitted the original 10 item model.  
Internal consistency of the BMQ-AET was much improved compared to the original BMQ 
and convergent validity showed predicted direction of correlation, although correlation with 
BMQ-AET concerns scale was low. Acceptability was good.  Conclusions: The evaluation of
the BMQ-AET is encouraging, and could facilitate future research around adherence to AET.
Keywords: Beliefs about Medicines Questionnaire (BMQ), BMQ-AET, adherence, Adjuvant
Endocrine Therapy (AET), Evaluation, Factor Structure, Convergent validity
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Background:
Approximately 80% of breast cancers will be oestrogen receptor positive, and adjuvant 
endocrine therapy (AET) such as Tamoxifen and Aromatase Inhibitors are recommended
(Keen & Davidson, 2003). Adjuvant endocrine therapy taken for five years to ten years has 
proven effectiveness in preventing recurrence and decreasing mortality from breast 
cancer(Davies et al., 2013, Gray, 2013, Dowsett et al., 2009, ATAC group, 2008, Howell et. 
al., 2005, Coombes et. al., 2004, Goss et. al., 2003, Fisher et. al., 1996).  However, to gain 
these potential benefits women need to adhere to the medication as prescribed, and reported 
rates of non-adherence are relatively high. Reviews report that 10-50% of women either do 
not take the correct dosage at the prescribed frequency or discontinue therapy leading to a 
20% increase in mortality(Makubate et al., 2013, McCowan et al., 2008, Banning, 2012, 
Gotay & Dunn, 2011, Hadji, 2010, Chlebowski & Geller, 2006). 
Beliefs about medications as factors influencing patient adherence behaviour have been 
reported in various clinical groups(van-Dulmen et.al., 2007).  Investigating women’s beliefs 
about endocrine therapies is crucial to explore their perception of risk and perception of 
benefit from taking the medication, and develop interventions to improve adherence. 
The BMQ has been tested in a wide variety of patient populations and is a valid and 
reliable measure of medication beliefs(Horne & Weinman, 1999).  A recent meta-analytic 
review reports that across studies, higher adherence was associated with stronger 
perceptions of necessity of treatment, OR = 1.742, 95% CI [1.569, 1.934], p<0.0001, and 
fewer Concerns about treatment, OR = 0.504, 95% CI: [0.450, 0.564], p<0.0001. These 
relationships remained significant when data were stratified by study size, the country in 
which the research was conducted and the type of adherence measure used(Horne et al, 
2013).  While it has been used to assess the beliefs and perceptions of women taking 
endocrine therapy after breast cancer(Corter et. al., 2013, Wouter et. al., 2013, Grunfeld et
al., 2005), and in other cancers (Llewellyn McGurk Weinman, 2005, Llewellyn McGurk 
Weinman, 2007), no psychometric evaluation of this measure for this population has been 
reported.  
The BMQ-AET adapted wording of the BMQ Specific Concerns and BMQ Specific 
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Necessity items to be more relevant to women taking AET following breast cancer.  The 
current study aims to evaluate the factor structure, internal consistency, and acceptability 
of the BMQ-AET Specific scale in a sample of women prescribed AET for breast cancer.
Methods and Procedures:
Design:
A cross-sectional study was carried out to explore women’s experiences of AET.  As part 
of this study, women completed the BMQ-AET within a self-report postal questionnaire.
Sample: 
Participants included women aged 36-85 years taking adjuvant endocrine therapy 
following treatment for breast cancer.  These women had previously participated in the 
Joint Aches Cohort Study (JACS) looking at women’s experiences of joint aches, pain and
stiffness in breast cancer(Fenlon et al., 2014). During JACS, participants were asked to 
indicate their willingness to participate in future studies; we re-approached only this 
subsample for this adherence study.  All participants had been diagnosed with primary 
oestrogen receptive positive breast cancer, and had been prescribed adjuvant endocrine 
therapy.  Exclusion criteria included: women with more advanced cancer, women 
seriously ill with other conditions, and women who had a poor comprehension of English.
Procedure:
Ethical approval was gained from the University Research Ethics Committee (UREC).  
Informed consent was gained, and postal questionnaires were sent out in July 2014, with a
reminder sent after 3 weeks of non-response.  Participants took approximately 20 minutes 
to complete the questionnaire, which include a range of nominal and multiple choice 
questions asking about their experiences of taking AET, and two scales: the Medical 
Adherence Rating Scale (MARS)(Thompson Kulkami Sergejew, 2000) and the BMQ-
AET Specific scales.  
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Measures:
The Beliefs about Medicines Questionnaire (BMQ) was originally developed to aid 
understanding of people’s perception of medicine regimes, and to help understand 
adherence to medication.  It is an 18 item self-report measure of beliefs about medicine
(Horne & Weinman, 1999) derived from a pool of items representing commonly held 
beliefs about medication in a chronic illness sample (Asthmatic, Cardiac, Diabetic, Renal,
Psychiatric, and General)(Horne & Weinman, 1999). Specific (10 items) and General (8 
items) beliefs were analysed separately.  The measure comprises two sections, each 
divided into two subscales.  The BMQ-Specific comprises two five item subscales: the 
‘Specific Necessity’ subscale (i.e. beliefs about the necessity of taking that specific 
medication to remain healthy) and the ‘Specific Concerns’ subscale (i.e. concerns about 
the negative effects of taking that specific medication). The BMQ-General comprises two 
4-item subscales assessing beliefs that medicines are harmful which should not be taken 
continuously (General-Harm) and that medicines are overused by doctors (General-
Overuse). All items of the BMQ are rated on a 5-point likert scale where 1 represents 
strongly agree, and 5 represents strongly disagree. Scores obtained for the individual 
items are summed to give a total score for each subscale, and the two sections of the 
BMQ can be used in combination or separately.  
Table 1 identifies the modifications made to the original BMQ for the BMQ-AET.  The 
term ‘hormone treatment’ is used instead of AET, as the former is a more recognised 
terminology for this treatment among women. Changes were made in consultation with 
service users and the expert advisory team for this study that included a breast cancer 
surgeon, an oncologist, a GP, a health psychologist, a professor of cancer nursing, and a 
medical sociologist. Most items had minor changes to make the items relevant to the 
population.  However, the item ‘my life would be impossible without medicines’ was 
changed to ‘taking hormone treatment makes me feel I am taking positive steps to remain 
well’ because AET is not taken by women to reduce side effects of a condition, but to 
reduce the risk of recurrence of breast cancer and is therefore not relevant to this new 
population.  AET can often cause side effects that make it difficult to continue with the 
treatment and therefore adherence is more related to taking personal control to avoid the 
return of a condition rather than controlling a pre-existing condition; this factor was not 
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covered elsewhere and so deemed a relevant replacement item.   
Service users from Independent Cancer Patients’ Voice (n=2), cancer experts (n=4), and a 
representative from the  charity Breast Cancer Care evaluated the face validity of the 
modified items during the development of the questionnaire, with minor adjustment to the
final wordings made to ensure comprehension.  As items on the General beliefs subscale 
are not condition specific, it was not necessary to amend wording.
The Medical Adherence Report Scale (MARS-5) (Thompson 2000) assesses adherence to 
treatment and was used to provide a measure of convergent validity with the BMQ-AET . 
The MARS-5 consists of five general statements about suboptimal adherence behaviour (I
forget to take my AET medicine, I alter the dose of my AET medicine, I stop taking my 
AET medicine for a while, I decide to skip one of my AET tablets, I take AET less than 
prescribed) answered on a 5 point scale where 1 represents ‘always’, and 5 represents 
‘never’. Items were not summed but used individually in determining types of adherence 
and non-adherence.
Analysis:
COnsensus-based Standards for the selection of health Measurement INstruments 
(COSMIN) were used in the selection of evaluation methods for the analysis(Mokkink et 
al., 2010).  Principal Components Analysis (PCA) using direct oblimin rotation was used 
to explore the factor structure of the modified measure.  PCA was chosen over factor 
analysis because it offers a more pragmatic psychometric solution, reducing the number 
of observed variables to a smaller number of components (factors) which account for 
most of the observed variance, thus avoiding some of the potential problems of factor 
interdependency which are associated with other types of psychometric scale 
development methods(Bartholomew, 2002). Furthermore, this method mirrors that used in
the development and evaluation of the original BMQ(Horne & Weinman, 1999) and it 
was our intention to be able to compare across these two versions.
The resultant factors were subjected to internal consistency testing using Cronbach’s 
alpha tests. Convergent validity was explored by comparing correlation between the 
6
071017
BMQ-AET and MARS; due to non-parametricity of MARS data, Spearman’s correlation 
tests were used. 
Acceptability was examined by exploring missing data, floor/ceiling effects, and face 
validity was assessed through discussions with service users and clinicians during the 
development stage of the questionnaire.
Results:
Questionnaires were returned by 211 women (73%), all of whom completed the BMQ-AET 
scale and 206 completed the MARS.  The socio-demographic characteristics and health status
of responders are summarised in table 2:
Factor Analysis 
Standard diagnostic tests were run to ensure that the data were suitable for factor analysis. 
Both the Kaiser-Meyer-Olkin test of sampling adequacy (KMO=.791) and Bartlett's test of 
sphericity (p = <.001) indicated that the current data were indeed appropriate.  
As is usual practice, an initial scree plot analysis was undertaken suggesting a 2 factor 
solution was the most parsimonious fit for the data, and this corresponded with the factor 
structure of the original BMQ.  More recent practice has also been to consider a Parallel 
Analysis Monte Carlo simulation (using randomly generated data) to verify the number of 
required factors(Velicer Eaton Fava, 2000).  Using the method described by Hayton et al 
(2004)(Hayton Allen Scarpello, 2004) which employs an upper bound of the 95% confidence 
interval for eigenvalues, averaging across 100 random data sets, this procedure confirmed 
that two resultant factors were appropriate.
Table 3 shows the factor structure matrix (with Kaiser normalisation) resulting from the 
principle components analysis; this accounted for 56.936 of the total variance (individual 
factor variances also indicated).  Where items loaded onto multiple factors, they were 
retained only for the factor onto which they loaded most strongly. 
Analysis indicated that the factor structure of the BMQ-AET-specific items mapped exactly 
onto the factor structure of the original scale; the original subscale names were thus retained 
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whereby Factor 1 became the concerns subscale, and Factor 2 became the necessity scale.  
Only one item loaded with a very low factor loading (‘Hormone treatment is a mystery to 
me’: .283) with the remainder meeting recommended criteria (Stevens Erlbaum, 1992). The 
low factor loading item was included in the final measure as removing this item did not 
improve overall psychometric properties of the scale, so it was retained to uphold the original
structure of the measure.
Internal consistency
Cronbach’s alpha’s statistics provide an indication of how well items within a given scale are 
measuring a similar and stable construct.  Typically, subscales with a Cronbach’s alpha of less
than .7 are considered inadequate, however, Cortina (1993) notes that the method of 
calculating this statistic is biased by item numbers whereby factors on a scale with fewer 
items tend usually to produce a lower alpha coefficient as a bi-product of the statistical 
calculation(Cortina, 1993).  As our two subscales of specific beliefs scored alpha coefficients 
of .776 and .795 for concerns and necessity respectively; even when bearing in mind 
Cortina’s caution (which is relevant given that only 5 items appear in each subscale), these 
two scales exceed the usual cut-off for acceptability reliability.  These figures are aligned 
with, and in some cases exceed, those reported in the confirmatory factor analysis reported by
Horne et al (1999)(Horne & Weinman, 1999).
Convergent Validity
The MARS is a self-report scale of adherence to medication and so provided an adequate 
measure of convergent validity for these data, whereby we would anticipate a negative 
correlation between both specific concerns and adherence, and a positive correlation between 
specific necessity beliefs and adherence. Correlations tests indicated a significant correlation 
between higher treatment necessity beliefs (BMQ-AET Specific Necessity) and greater 
adherence (MARS) scores (rs= 0.215, p=.001).  However, correlations between BMQ-AET 
Specific Concerns and MARS, while showing the expected direction of association (higher 
treatment concern beliefs correlated with lower adherence scores), failed to reach statistical 
significance (rs= -0.038, p=.100).
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Acceptability 
Acceptability of the two individual scales was determined by examining the rate of missing 
responses to each item, as this provides an indicator of how acceptable the instrument is in a 
given population(Fitpztrick et al, 1998).  The BMQ-AET was completed by all 211 
respondents, with only 5 cases having missing responses for one or more items.
Floor and ceiling effects (i.e. the percentage scoring the minimum and maximum score) were 
examined for the BMQ-AET Specific Concerns and the BMQ-AET Specific Necessity. The 
Specific Concerns scale had a 3.4% ceiling effect and a 1% floor effect;  The Specific 
Necessity had a 0% ceiling effect and a 8.7% floor effect.   As a proportion of up to 15% can 
be considered a low effect(Terwee et al, 2007), the data shows acceptable ceiling and floor 
effects.  
Discussion
The BMQ-AET was included in a questionnaire survey to explore women’s experiences and 
views of taking AET to identify factors that may be associated with adherence or non-
adherence.  Independent testing of the BMQ for women prescribed AET following breast 
cancer has not previously been reported.  The BMQ was modified so the wording was 
suitable to women who were taking AET.  The evaluation of the BMQ-AET showed a similar
factor structure to the original BMQ Specific subscale(Horne & Weinman, 1999), and we 
report good internal consistency, encouraging convergent validity and good acceptability 
within this sample.  The modified scale may therefore provide a valuable assessment of 
women’s specific beliefs around AET.
The results show all factors had sufficient factor loading to be included and therefore the 
original factor structure proposed by Horne (1999) was retained(Horne & Weinman, 1999).  
This is an important finding as it suggests that the factors represent ‘core themes’ 
underpinning common representations of Specific Beliefs in this population which may 
generalise out to other specific condition groups.  One item ‘my life would be impossible 
without medicines’ was changed to ‘taking hormone treatment makes me feel I am taking 
positive steps to remain well’ because AET is not taken by women to reduce side effects of a 
condition, but to reduce the risk of recurrence of breast cancer and is therefore not relevant to 
this new population.  AET can often cause side effects that make it difficult to continue with 
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the treatment and therefore adherence is more related to taking personal control to avoid the 
return of a condition rather than controlling a pre-existing condition.  Although the meaning 
of the item is slightly different, our psychometric analysis of the scale demonstrates that the 
new item is still correlated with the other cluster items within the factor group. As such we 
would suggest that whilst the new item represents some deviation, it is both a pragmatic and 
psychometrically valid alternation to make the scale relevant to this patient population.
Other studies have reported similar findings in primary care, general medical populations, 
and mental health populations in the UK and across cultures (Salgado et al, 2013, Cuevas et 
al, 2011, Browne et al, 2005).  In this study, the only exception to this was the item ‘Hormone
treatment is a mystery to me’  and so this may require some further investigation in future 
uses of the scale.  Internal consistency exceeded that reported by Horne in the original 
evaluation of the measure, which has also been reported in other patient populations, 
including Stroke and Asthma indicating the generalisability of the BMQ(Sjölander Eriksson 
Glader, 2013, Horne & Weinman, 2002).  Furthermore, results reported good completion 
rates, acceptable ceiling and floor effects.  Face validity of the modified scale was confirmed 
prior to completion of the questionnaire through consultation with service users and health 
professionals in the advisory group for this study.
Correlation between BMQ-AET specific subscales and MARS were in the predicted direction, 
although only the association between treatment necessity beliefs and adherence reached significance.
The low correlation between treatment concern beliefs and adherence may have been due to the 
subjective nature of capturing non-adherence on self-reported measures such as the MARS. 
Correlation with objective measures, such as pill counts, may provide a better gold standard in future 
studies. A recent meta-analysis reported significant correlation between both Concerns and Necessity 
in 33 and 31 studies correlating with MARS(Horne et al, 2013). However, they concluded that 
stratifying by long term condition and adherence measurement revealed a need for further studies 
using objective measures in longer term conditions to ensure greater accuracy of measuring non-
adherence long-term. Furthermore, a larger study may have given greater power to the study at which 
point we may expect these effects to more likely reach statistical significance cut-offs.  A further 
meta-analysis exploring associations between the BMQ and different measures of medical adherence 
concluded that they were correlated at a population level and across the majority of included 
conditions(Foot et al, 2015).
10
071017
The current work is based on a self-selected sample that may have presented response bias. 
The majority of the sample were white Caucasians, so may not be generalizable to ethnic 
minority groups. While this study reports a correlation between the modified BMQ specific 
subscales and MARS in the predicted direction, more studies, possibly with larger samples 
may improve the statistical power to gain significance in both the BMQ-AET Necessity and 
the BMQ-AET Concerns.  Further confirmatory factor analysis is also advised to ensure that 
this factor structure is retained across multiple samples with less exploratory methods of 
statistical modelling.  Additional studies investigating the psychometric properties of BMQ in
other settings and populations may be beneficial to confirm our finding that suggests beliefs 
provide ‘core themes’ which are not necessarily population specific.
In conclusion, the BMQ-AET for women prescribed AET following breast cancer has good 
internal consistency, encouraging convergent validity and good acceptability for the Specific 
Beliefs about the necessity of and concerns regarding taking AET, and could facilitate future 
research in this field. Women are prescribed AET for between 5 and 10 years after 
completion of primary cancer treatment(Gray, 2013, Davies et al., 2013, Goss et al, 2005) and
adherence over the entire course is generally low, with consequent increased risk of cancer 
recurrence and mortality(Makubate et al, 2013, Hershamn et al, 2010, McCowan et al., 2008, 
Partridge et al, 2003). Reasons for not adhering to AET need to be investigated at an 
individual and population level. The BMQ-AET evaluated in this paper could facilitate a 
better understanding of factors which affect adherence to AET following breast cancer, to 
help develop interventions to support patients in engaging with this treatment and coping 
with the challenging side effects that might result.
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Table 1: Original Specific BMQ (Horne) and Modified Specific BMQ items for women 
taking AET.
Original BMQ Specific Modified BMQ Specific (BMQ-AET)
My health at present depends on 
medicines
My health at present depends on me 
taking hormone treatment
Having to take this medicine worries me Having to take hormone treatment worries
me
My life would be impossible without 
medicines
Taking hormone treatment makes me feel 
I am taking positive steps to remain well
Without my medicines I would be very ill Without taking hormone treatment I 
would be more likely to develop breast 
cancer again
I sometimes worry about the long term 
effects of taking medicines
I sometimes worry about long term effects
of taking hormone treatment
My medicines are a mystery to me Hormone treatment is a mystery to me
My health in the future is dependent on 
my medicines
My health in the future will depend on me
taking hormone treatment
My medicines disrupt my life Taking hormone treatment disrupts my life
I sometime worry about becoming too 
dependent on medicines
I sometimes worry about having hormone 
treatment  over a long period of time
My medicines protect me from becoming 
worse
Hormone treatment protects me from 
becoming ill
BMQ=Beliefs about Medicine Questionnaire
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Table 2: Demographics and clinical data (n=211) 
Total
(N=211)
Non-adherers
(N=46)
Adherers
(N=165)
Age
Range
Median
36-50 years
51-64 years
≥65 years
Not provided
36 to 85 years 
63 years
31 (15%) 
80 (38%)
87 (41%) 
13 (6%)
13 (28%)
19 (41%)
14 (30%)
18 (11%)
61 (37%)
73 (44%)
Marital status
Married
Divorced
Widowed
Single
167 (79%)
21 (10%) 
13 (6%) 
10 (5%) 
37 (80%)
3 (7%)
2  (4%)
4  (9%)
130 (79%)
18   (11%) 
11  (7%)
6   (4%)
Employment 
status:
Retired
Paid work
Sick leave/unable 
to work
Unemployed
Other
105 (50%) 
87 (41%) 
9 (4%) 
2 (1%) 
8 (4%) 
17 (37%)
23 (14%)
3   (7%)
3   (7%)
88 (53%) 
64 (39%)
6   (4%)
2   (1%)
5   (3%)
Education
‘0’ level
‘A’ level
College/University
Post-graduate
Other
Not provided
77 (37%) 
33 (16%) 
37 (18%) 
24 (11%) 
32 (15%) 
8  (4%)
15  (33%)
12  (26%)
7  (15%)
7  (15%)
5  (11%)
62  (38%)
21  (13%)
30  (18%)
17  (10%)
35  (21%)
Ethnic 
background:
White British
Other
207 (98%) 
3 (2%)  
46  (100%) 161 (98%)
3  (2%)
Diagnosis status
In breast only
In breast and 
lymph nodes
146 (69%) 
65 (31%) 
35  (76%)
11 (24%) 
111 (67%)
54  (33%)
AET therapy:
Tamoxifen 
Aromatase 
Inhibitors
Not sure
Switched type of 
AET taken
125 (59%) 
79 (37%) 
7 (3%)   
23 (11%) 
35 (76%)
9 (20%)
2 (4%)
7 (14%)
90 (55%)
70 (42%)
5 (3%)
15 (9%)
Date started:
2009
2010
2011
2012
5 (2%) 
54 (26%) 
110 (52%) 
42 (20%) 
1 (2%)
17 (30%)
18 (32%)
10 (22%)
4 (2%)
37 (22%)
92 (56%)
32 (19%)
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Table 3.  Factor structure obtained by principal components analysis of the BMQ-AET 
specific items (highest factor loading indicated in emboldened text)
Factor 1 Factor 2
Specific-Concerns
I sometimes worry about 
long term effects of taking 
hormone treatment
.848 -.242
Having to take hormone 
treatment worries me
.863 -.201
I sometimes worry about 
having hormone treatment  
over a long period of time
.890 -.212
Taking hormone treatment 
disrupts my life
.658 -.023
Hormone treatment is a 
mystery to me
.283 -.011
Specific-Necessity
Taking hormone treatment 
makes me feel I am taking 
positive steps to remain well
-.484 .541
Without taking hormone 
treatment I would be more 
likely to develop breast 
cancer again
-.157 .734
My health at present depends
on me taking hormone 
treatment
-.001 .784
Hormone treatment protects 
me from becoming ill
-.161 .781
My health in the future will 
depend on me taking 
hormone treatment
-.128 .817
TOTAL VARIANCE 
EXPLAINED
35.375 21.562
BMQ=Beliefs about Medicine Questionnaire
17
